샘플 요청 목록

 카트 문의
시장보고서
상품코드
1949478

펩타이드 치료제 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 용도별, 유형별, 제조업체별, 투여 경로별, 합성 기술별, 지역별＆경쟁(2021-2031년)

Peptide Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Type, By Type of Manufacturers, By Route of Administration, By Synthesis Technology, By Region & Competition, 2021-2031F
발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 펩타이드 치료제 시장은 견고성장이 전망되고 있어 2025년 569억 달러에서 2031년에는 967억 3,000만 달러로 성장하고, CAGR 9.25%를 나타낼 것으로 예측됩니다.

이들 치료제는 짧은 아미노산 사슬로 구성된 선택적 신호전달 분자로 정의되며, 높은 효능과 최소한의 독성으로 특정 생리적 기능을 조절하는 능력으로 높은 평가를 받고 있습니다. 시장 확대는 만성 대사성 질환, 특히 당뇨병과 비만의 유병률 증가로 인해 표적 수용체 작용제에 대한 수요가 급증하고 있습니다. 또한, 합성 제조 기술의 발전으로 생산 장벽이 낮아져 보다 광범위한 상업적 활용이 가능해졌습니다. 미국화학회(ACS)의 보고에 따르면, 2023년 FDA는 9개의 펩타이드 및 올리고뉴클레오타이드 치료제를 승인했으며, 이는 연간 신약 승인 건수의 16%를 차지합니다.

시장 개요
예측 기간 2027-2031년
시장 규모 : 2025년 569억 달러
시장 규모 : 2031년 967억 3,000만 달러
CAGR : 2026-2031년 9.25%
가장 성장이 빠른 부문 대사성 질환
최대 시장 북미

이러한 긍정적인 전망에도 불구하고, 업계는 약물 전달 및 안정성과 관련하여 심각한 문제에 직면해 있습니다. 펩타이드는 일반적으로 경구 생체 이용률이 낮고, 효소 분해에 의해 혈류에서 빠르게 제거되기 때문에 자주 침습적인 주사를 맞아야 하는 경우가 많습니다. 이러한 비경구 투여의 필요성은 환자의 순응도를 복잡하게 만들고, 만성 질환 관리에서 펩타이드 기반 치료법의 광범위한 적용을 제한하고 있습니다. 따라서 장기 치료 요법의 편의성과 유효성을 높이려는 이 분야에서는 이러한 약동학적 한계를 극복하는 것이 여전히 중요한 과제로 남아있습니다.

시장 성장 촉진요인

세계적으로 증가하는 대사성 질환 및 만성 질환, 특히 2형 당뇨병과 비만 발생률이 시장 확대의 주요 동력이 되고 있습니다. 이러한 질병 부담 증가로 인해 식욕 조절 및 인슐린 분비 촉진 효과로 알려진 글루카곤 유사 펩타이드-1(GLP-1) 수용체 작용제에 대한 임상적 관심이 높아지고 있습니다. 그 결과, 주요 제약사들은 대사 펩타이드 부문에서 큰 폭의 매출 성장을 이루고 있으며, 생산 규모 확대의 필요성이 대두되고 있습니다. 예를 들어, 노보 노디스크의 2023년 연례 보고서에 따르면, 2024년 2월 기준 비만 치료제 부문 매출은 환율 조정 후 154% 증가한 416억 덴마크 크로네에 달할 것으로 예상되며, 이는 비만 치료제가 생활습관병 관리에서 차지하는 중요한 역할과 표적 생물학적 분자로부터 얻은 상업적 성공을 뒷받침합니다. 을 뒷받침하고 있습니다.

두 번째 촉진요인은 바이오의약품 연구개발의 활발한 확대와 혁신적인 펩타이드 자산을 확보하기 위한 전략적 인수합병(M&A)입니다. 주요 제약사들은 차세대 이중 작용제 및 삼중 작용제에 대한 접근성을 확보하기 위해 전문 바이오텍 기업 인수를 적극적으로 추진하고 있으며, 이러한 전략은 초기 단계의 리스크를 줄이고 제품 출시를 앞당길 수 있습니다. 특히 2023년 12월 로슈가 펩타이드 개발사 카모트 테라퓨틱스를 27억 달러에 인수하기로 합의하면서 업계가 기존 인슐린을 넘어선 파이프라인 확장에 집중하고 있음을 보여주었습니다. 이러한 성장을 뒷받침하기 위해 각 제조업체들은 인프라 구축에도 많은 투자를 하고 있습니다. 2023년 11월, Eli Lilly & Company는 독일에 새로운 제조 시설을 건설하기 위해 25억 달러를 투자하겠다고 발표했으며, 특히 비경구용 펩타이드공급 능력을 강화하기 위해 노력하고 있습니다.

시장의 과제

세계 펩타이드 치료제 시장의 주요 장벽은 펩타이드 분자의 본질적인 불안정성과 이에 따른 심각한 약물 전달의 어려움에 있습니다. 펩타이드는 소화관 및 순환계 내 효소에 의해 빠르게 분해되기 쉽기 때문에 경구 생체 이용률이 제한적이고 반감기가 짧다는 단점이 있습니다. 그 결과, 약물이 충분한 효능으로 표적 부위에 도달할 수 있도록 피하주사나 정맥주사 등 침습적인 투여방법이 필요한 경우가 많습니다. 이러한 잦은 주사에 대한 의존성은 특히 장기 치료가 필요한 만성 질환에서 환자의 복약 순응도에 큰 장벽이 되어 대상 환자층을 제한하고 전체 시장 침투를 저해하고 있습니다.

또한, 안정적이고 효과적인 전달 시스템 개발에 수반되는 복잡성으로 인해 새로운 제품이 규제 경로를 통과하는 속도가 느려지고 있습니다. 이러한 분자의 제형화에 대한 도전은 승인 통계에도 반영되어 있습니다. 규제업무전문가협회(RAPS)에 따르면, 2024년 FDA의 승인을 받은 신규 펩타이드 치료제는 단 2개 품목에 불과하며, 이는 같은 해 승인된 50개의 신규 분자 실체의 4%에 불과합니다. 기존 저분자 화합물에 비해 낮은 승인률은 개발자들이 안정성 문제를 해결하는 데 있어 지속적인 어려움을 겪고 있으며, 이는 상업적 시장에 성공적으로 진입할 수 있는 새로운 치료제의 수에 직접적인 제한을 가하고 있습니다.

시장 동향

인공지능을 펩타이드 신약개발에 접목함으로써 막투과성 최적화, 대사 안정성 등 오랜 숙제를 해결하고 연구개발의 지형을 바꾸고 있습니다. 첨단 계산 플랫폼을 통해 방대한 가상 라이브러리를 신속하게 스크리닝하여 물리적 합성 전에 우수한 결합 친화성과 약동학적 특성을 가진 후보 화합물을 식별할 수 있게 되었습니다. 이러한 기술적 진화를 통해 개발자들은 신약 개발 일정을 단축하고, 초기 개발 단계에서 흔히 발생하는 높은 실패율을 줄일 수 있습니다. 이러한 추세를 보여주는 사례로 바이오듀로사는 2025년 8월 아톰비트와의 전략적 제휴를 발표했습니다. 1조 개 이상의 잠재적 펩타이드 화합물을 평가할 수 있는 AI 기반 플랫폼을 도입하여 실용적인 치료 후보물질 발굴을 가속화할 수 있습니다.

동시에 차세대 펩타이드 약물 복합체(PDC)의 등장은 표적 종양학에서 중요한 진전을 보이고 있습니다. 단순한 수용체 작용제에서 세포독성 물질이나 방사성 물질을 암세포로 직접 운반하는 복잡한 약물 전달 시스템으로 전환되고 있습니다. PDC는 항체-약물 복합체와 비교하여 조직 깊숙이 침투하고 빠르게 전신으로 제거되는 장점이 있으며, 고형 종양에 대한 효능을 유지하면서 표적 외 독성을 최소화하는 데 도움이 됩니다. 이러한 추세는 방사성 리간드 치료와 혁신적인 링커 기술에 대한 임상연구가 눈에 띄게 증가하면서 두드러지게 나타나고 있습니다. 2025년 6월 WuXi AppTec 보고서에 따르면, 2024년에는 30개 이상의 방사성 리간드 약물 복합체 임상시험이 시작될 것으로 예상되며, 이는 지난 5년 대비 3배 증가한 수치입니다.

자주 묻는 질문

  • 세계의 펩타이드 치료제 시장 규모는 어떻게 예측되나요?
  • 펩타이드 치료제 시장의 주요 성장 촉진 요인은 무엇인가요?
  • 펩타이드 치료제 시장에서의 주요 과제는 무엇인가요?
  • 펩타이드 치료제 시장의 최근 동향은 어떤가요?
  • 펩타이드 치료제 시장에서 주요 기업은 어디인가요?

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 펩타이드 치료제 시장 전망

제6장 북미의 펩타이드 치료제 시장 전망

제7장 유럽의 펩타이드 치료제 시장 전망

제8장 아시아태평양의 펩타이드 치료제 시장 전망

제9장 중동 및 아프리카의 펩타이드 치료제 시장 전망

제10장 남미의 펩타이드 치료제 시장 전망

제11장 시장 역학

제12장 시장 동향과 발전

제13장 세계의 펩타이드 치료제 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

제15장 경쟁 구도

제16장 전략적 제안

제17장 회사 소개 및 면책조항

LSH 26.03.12

The Global Peptide Therapeutics Market is projected to experience robust growth, advancing from a valuation of USD 56.90 Billion in 2025 to USD 96.73 Billion by 2031, reflecting a compound annual growth rate of 9.25%. These therapeutics, defined as selective signaling molecules comprised of short amino acid chains, are valued for their ability to regulate specific physiological functions with high potency and minimal toxicity. The market's expansion is largely fueled by the increasing prevalence of chronic metabolic disorders, particularly diabetes and obesity, which has surged the demand for targeted receptor agonists. Additionally, advancements in synthetic manufacturing techniques are reducing production hurdles, thereby enabling wider commercial availability. Highlighting this momentum, the American Chemical Society reported that in 2023, the FDA approved nine peptide and oligonucleotide therapeutics, accounting for 16% of the year's total new drug approvals.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 56.90 Billion
Market Size 2031USD 96.73 Billion
CAGR 2026-20319.25%
Fastest Growing SegmentMetabolic Disorders
Largest MarketNorth America

Despite this positive outlook, the industry confronts significant obstacles regarding drug delivery and stability. Peptides generally suffer from low oral bioavailability and are quickly cleared from the bloodstream due to enzymatic degradation, often requiring frequent invasive injections. This necessity for parenteral administration complicates patient compliance and restricts the broader application of peptide-based therapies in managing chronic conditions. Consequently, overcoming these pharmacokinetic limitations remains a pivotal challenge for the sector as it seeks to enhance the convenience and effectiveness of long-term treatment regimens.

Market Driver

The surging global incidence of metabolic and chronic conditions, particularly type 2 diabetes and obesity, acts as a primary catalyst for market expansion. This increasing disease burden has directed clinical attention toward Glucagon-like peptide-1 (GLP-1) receptor agonists, known for their efficacy in regulating appetite and insulin secretion. As a result, major pharmaceutical companies are seeing substantial revenue growth from their metabolic peptide divisions, prompting a need for scaled-up production. For instance, Novo Nordisk's 2023 Annual Report revealed that sales within its Obesity Care division rose by 154% at constant exchange rates to 41.6 billion Danish kroner in February 2024, underscoring the vital role these therapeutics play in lifestyle disease management and the commercial success derived from these targeted biological molecules.

A secondary driver is the vigorous expansion of biopharmaceutical research and development, coupled with strategic mergers and acquisitions designed to secure innovative peptide assets. Major pharmaceutical corporations are actively acquiring specialized biotech firms to gain access to next-generation dual and triple agonists, a strategy that mitigates early-stage risks and accelerates product launches. Notably, in December 2023, Roche agreed to acquire the peptide developer Carmot Therapeutics for an upfront payment of 2.7 billion US dollars, demonstrating the industry's dedication to broadening pipelines beyond traditional insulin. To support this growth, manufacturers are also heavily investing in infrastructure; in November 2023, Eli Lilly and Company pledged 2.5 billion dollars to build a new manufacturing facility in Germany, specifically to enhance its parenteral peptide supply capabilities.

Market Challenge

The primary obstacle impeding the Global Peptide Therapeutics Market is the intrinsic instability of peptide molecules combined with significant drug delivery difficulties. Peptides are prone to rapid degradation by enzymes in the gastrointestinal tract and circulation, leading to limited oral bioavailability and brief half-lives. Consequently, invasive administration methods such as subcutaneous or intravenous injections are often required to ensure the medication reaches its intended target with adequate potency. This reliance on frequent injections poses a substantial hurdle to patient adherence, especially for chronic conditions requiring long-term treatment, which in turn restricts the addressable patient base and hampers overall market penetration.

Furthermore, the complexity involved in developing stable and effective delivery systems retards the progress of new products through regulatory pathways. The challenge of formulating these molecules is reflected in approval statistics; according to the Regulatory Affairs Professionals Society, only two novel peptide therapeutics received FDA approval in 2024, comprising a mere 4% of the 50 new molecular entities authorized that year. This low approval rate relative to traditional small molecules highlights the enduring struggle developers face in resolving stability concerns, directly limiting the number of new therapies that successfully enter the commercial market.

Market Trends

The incorporation of artificial intelligence into peptide discovery is transforming the research and development landscape by addressing longstanding challenges such as optimizing membrane permeability and metabolic stability. Advanced computational platforms now facilitate the rapid screening of extensive virtual libraries, allowing researchers to pinpoint candidates with superior binding affinity and pharmacokinetic properties prior to physical synthesis. This technological evolution enables developers to shorten discovery schedules and decrease the high failure rates typical of early-stage development. Illustrating this trend, BioDuro announced a strategic partnership with Atombeat in August 2025, deploying an AI-driven platform capable of evaluating over one trillion potential peptide compounds to accelerate the identification of viable therapeutic candidates.

Simultaneously, the emergence of next-generation Peptide Drug Conjugates (PDCs) marks a significant advancement in targeted oncology, transitioning from simple receptor agonists to complex delivery systems that transport cytotoxic or radioactive agents directly to cancer cells. Compared to antibody-drug conjugates, PDCs offer advantages such as deeper tissue penetration and more rapid systemic clearance, which help minimize off-target toxicity while maintaining potency against solid tumors. This trend is highlighted by a marked increase in clinical efforts surrounding radioligand therapies and innovative linker technologies; a June 2025 report by WuXi AppTec noted that over 30 radioligand drug conjugate clinical trials were initiated in 2024, representing a threefold increase over the previous five years.

Key Market Players

  • Eli Lilly and Co.
  • Pfizer Inc.
  • Amgen Inc.
  • Takeda Pharmaceutical Co Ltd.
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • F Hoffmann-La Roche AG
  • Novartis AG
  • Novo Nordisk A/S

Report Scope

In this report, the Global Peptide Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Peptide Therapeutics Market, By Application

  • Cancer
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Respiratory Disorders
  • Gastrointestinal Disorders
  • Infectious Diseases
  • Pain
  • Dermatological Disorders
  • Neurological Disorders
  • Renal Disorders
  • Others

Peptide Therapeutics Market, By Type

  • Generic
  • Innovative

Peptide Therapeutics Market, By Type of Manufacturers

  • In-house
  • Outsourced

Peptide Therapeutics Market, By Route of Administration

  • Parenteral Route
  • Oral Route
  • Pulmonary
  • Mucosal
  • Others

Peptide Therapeutics Market, By Synthesis Technology

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Peptide Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptide Therapeutics Market.

Available Customizations:

Global Peptide Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Peptide Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Cancer, Metabolic Disorders, Cardiovascular Disorders, Respiratory Disorders, Gastrointestinal Disorders, Infectious Diseases, Pain, Dermatological Disorders, Neurological Disorders, Renal Disorders, Others)
    • 5.2.2. By Type (Generic, Innovative)
    • 5.2.3. By Type of Manufacturers (In-house, Outsourced)
    • 5.2.4. By Route of Administration (Parenteral Route, Oral Route, Pulmonary, Mucosal, Others)
    • 5.2.5. By Synthesis Technology (Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), Hybrid Technology)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Peptide Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Type
    • 6.2.3. By Type of Manufacturers
    • 6.2.4. By Route of Administration
    • 6.2.5. By Synthesis Technology
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Peptide Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Type of Manufacturers
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By Synthesis Technology
    • 6.3.2. Canada Peptide Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Type of Manufacturers
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By Synthesis Technology
    • 6.3.3. Mexico Peptide Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Type of Manufacturers
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By Synthesis Technology

7. Europe Peptide Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Type
    • 7.2.3. By Type of Manufacturers
    • 7.2.4. By Route of Administration
    • 7.2.5. By Synthesis Technology
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Peptide Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Type of Manufacturers
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By Synthesis Technology
    • 7.3.2. France Peptide Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Type of Manufacturers
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By Synthesis Technology
    • 7.3.3. United Kingdom Peptide Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Type of Manufacturers
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By Synthesis Technology
    • 7.3.4. Italy Peptide Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Type of Manufacturers
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By Synthesis Technology
    • 7.3.5. Spain Peptide Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Type of Manufacturers
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By Synthesis Technology

8. Asia Pacific Peptide Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Type
    • 8.2.3. By Type of Manufacturers
    • 8.2.4. By Route of Administration
    • 8.2.5. By Synthesis Technology
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Peptide Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Type of Manufacturers
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By Synthesis Technology
    • 8.3.2. India Peptide Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Type of Manufacturers
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By Synthesis Technology
    • 8.3.3. Japan Peptide Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Type of Manufacturers
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By Synthesis Technology
    • 8.3.4. South Korea Peptide Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Type of Manufacturers
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By Synthesis Technology
    • 8.3.5. Australia Peptide Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Type of Manufacturers
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By Synthesis Technology

9. Middle East & Africa Peptide Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Type
    • 9.2.3. By Type of Manufacturers
    • 9.2.4. By Route of Administration
    • 9.2.5. By Synthesis Technology
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Peptide Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Type of Manufacturers
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By Synthesis Technology
    • 9.3.2. UAE Peptide Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Type of Manufacturers
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By Synthesis Technology
    • 9.3.3. South Africa Peptide Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Type of Manufacturers
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By Synthesis Technology

10. South America Peptide Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Type
    • 10.2.3. By Type of Manufacturers
    • 10.2.4. By Route of Administration
    • 10.2.5. By Synthesis Technology
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Peptide Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Type of Manufacturers
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By Synthesis Technology
    • 10.3.2. Colombia Peptide Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Type of Manufacturers
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By Synthesis Technology
    • 10.3.3. Argentina Peptide Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Type of Manufacturers
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By Synthesis Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Peptide Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Eli Lilly and Co.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Amgen Inc.
  • 15.4. Takeda Pharmaceutical Co Ltd.
  • 15.5. AstraZeneca Pharmaceuticals LP
  • 15.6. Teva Pharmaceutical Industries Ltd.
  • 15.7. Sanofi S.A.
  • 15.8. F Hoffmann-La Roche AG
  • 15.9. Novartis AG
  • 15.10. Novo Nordisk A/S

16. Strategic Recommendations

17. About Us & Disclaimer

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제